At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
WGS GeneDx Holdings
Not Yet Opened 09-18 16:00:00 EDT
101.10
-3.85
-3.67%
盘后101.10
+0.000.00%
19:56 EDT
High105.00Low99.70Vol786.13K
Open104.59D1 Closing104.95Amplitude5.05%
Mkt Cap3.00BTradable Cap2.07BTotal Shares29.68M
T/O79.68MT/O Rate3.84%Tradable Shares20.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

GeneDx, Beren Therapeutics launch NPC GenomeComplete
TIPRANKS  ·  09-09
GeneDx, Beren Therapeutics launch NPC GenomeComplete
GeneDx and Beren Therapeutics Launch Npc Genomecomplete to Improve Diagnosis of Niemann-Pick Disease Type C
THOMSON REUTERS  ·  09-09
GeneDx and Beren Therapeutics Launch Npc Genomecomplete to Improve Diagnosis of Niemann-Pick Disease Type C
GeneDx announces data published in Genetics in Medicine on genome sequencing
TIPRANKS  ·  08-24
GeneDx announces data published in Genetics in Medicine on genome sequencing
GeneDx Study Supports Hospital-Wide Rapid Genome Sequencing Adoption at Seattle Children’s
Reuters  ·  08-24
GeneDx Study Supports Hospital-Wide Rapid Genome Sequencing Adoption at Seattle Children’s
Genedx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children
Reuters  ·  08-11
Genedx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children
GeneDx launches new online offering to expand accessibility of exome testing
TIPRANKS  ·  08-11
GeneDx launches new online offering to expand accessibility of exome testing
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
THOMSON REUTERS  ·  08-11
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
GlobeNewswire  ·  08-07
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
GeneDx to Present at Canaccord Genuity Growth Conference Fireside Chat
Reuters  ·  08-07
GeneDx to Present at Canaccord Genuity Growth Conference Fireside Chat
GeneDx Holdings Price Target Maintained with a $90.00/Share by BTIG
Dow Jones  ·  08-04
GeneDx Holdings Price Target Maintained with a $90.00/Share by BTIG
GeneDx Holdings Corp : Canaccord Genuity Raises Target Price to $90 from $75
THOMSON REUTERS  ·  08-04
GeneDx Holdings Corp : Canaccord Genuity Raises Target Price to $90 from $75
GeneDx Holdings Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-04
GeneDx Holdings Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
Benzinga Earnings  ·  08-04
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million
MT Newswires Live  ·  08-04
GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million
GeneDx Q2 FY26 GAAP Net Loss Widens to $17.7 Million; Revenue Rises 11% Year over Year to $114.4 Million
Reuters  ·  08-04
GeneDx Q2 FY26 GAAP Net Loss Widens to $17.7 Million; Revenue Rises 11% Year over Year to $114.4 Million
GeneDx Q2 Revenue Beats Analyst Estimates
Reuters  ·  08-04
GeneDx Q2 Revenue Beats Analyst Estimates
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
Benzinga Earnings  ·  08-04
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 Million
Reuters  ·  08-04
GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 Million
GeneDx: Q3 2026 Revenue Guidance $122 Mln-$124 Mln
THOMSON REUTERS  ·  08-04
GeneDx: Q3 2026 Revenue Guidance $122 Mln-$124 Mln
GeneDx Holdings: Reaffirmed Its Full Year 2026 Guidance
THOMSON REUTERS  ·  08-04
GeneDx Holdings: Reaffirmed Its Full Year 2026 Guidance

Introduction

Company Name.
GeneDx Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.
Issue price:
--